SIGA to Host Fourth Quarter and Year End Business Update Call on March 6, 2013

SIGA to Host Fourth Quarter and Year End Business Update Call on March 6, 2013

NEW YORK, March 1, 2013 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc.
(Nasdaq:SIGA), a company specializing in the development of pharmaceutical
agents to fight lethal disease causing pathogens, announced today that
management will host a conference call and simultaneous webcast to provide a
quarterly business update at 4:30 P.M. EST on Wednesday, March 6, 2013.

Participants should call (877) 303-9231 (United States/Canada) or (760)
666-3567 (International) and request the SIGA call or provide confirmation
code 18138617. A live broadcast of the call will be available on the Company's
website at under the 'Events & Presentations' tab in the Investor
Relations section.

A replay of the call will be available approximately two hours after the call
and will be accessible until 11:59 P.M. ET on March 20, 2013. To listen to the
replay, dial (855) 859-2056 (Domestic) or (404) 537-3406 (International) and
enter the code 18138617. The webcast of the event will also be archived on the
Company's website for two weeks under the 'Events & Presentations' tab in the
Investor Relations section.

About SIGA Technologies, Inc.

In the United States and around the globe, populations face a serious but
unmet need for new drugs to protect against potentially catastrophic emerging
viral pathogens and biological weapons of mass destruction. We are a
pharmaceutical company specializing in developing pharmaceutical solutions for
some of the most lethal disease causing pathogens in the world - smallpox,
Ebola, dengue, Lassa fever and other dangerous viruses. Our objective is to
discover, develop, manufacture and commercialize drugs to prevent and treat
these high-priority threats. Our mission is to disarm dreaded viral diseases
and create robust, modern biodefense countermeasures. For more information
about SIGA, please visit SIGA's web site at

The SIGA Technologies, Inc. logo is available at

Forward-looking Statements

This press release contains certain "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995, as amended,
including statements relating to the outcome of the litigation with
PharmAthene, Inc. Forward-looking statements are based on management's
estimates, assumptions and projections, and are subject to uncertainties, many
of which are beyond our control. Actual results may differ materially from
those anticipated in any forward-looking statement. Factors that may cause
such differences include (i) the risk that potential products that appear
promising to us or our collaborators cannot be shown to be efficacious or safe
in subsequent pre-clinical or clinical trials, (ii) the risk that we or our
collaborators will not obtain appropriate or necessary governmental approvals
to market these or other potential products, (iii) the risk that we may not be
able to obtain anticipated funding for our development projects or other
needed funding, (iv) the risk that we may not be able to secure funding from
anticipated or current government contracts and grants, (v) the risk that we
may not be able to secure or enforce sufficient legal rights in our products,
including patent protection, (vi) the risk that any challenge to our patent
and other property rights, if adversely determined, could affect our business
and, even if determined favorably, could be costly, (vii) the risk that
regulatory requirements applicable to our products may result in the need for
further or additional testing or documentation that will delay or prevent
seeking or obtaining needed approvals to market these products, (viii) the
risk that one or more protests could be filed and upheld in whole or in part
or other governmental action taken, in either case leading to a delay of
performance under our contract with the Biomedical Advanced Research and
Development Authority (BARDA) or other governmental contracts, (ix) the risk
that our BARDA contract is modified or cancelled at the request or requirement
of the U.S. government, (x) the risk that the adverse portions of the
post-trial decision by the Delaware Chancery Court in the litigation brought
by PharmAthene, Inc. will be upheld in further proceedings, including any
appeal or cross-appeal, or that the favorable portions will be modified, (xi)
the risk that the volatile and competitive nature of the biotechnology
industry may hamper our efforts to develop or market our products, (xii) the
risk that changes in domestic and foreign economic and market conditions may
adversely affect our ability to advance our research or products, (xiii) the
effect of any change to federal, state or foreign regulation, including drug
regulation and international trade regulation, on our business, (xiv) the risk
that our outstanding indebtedness may make it more difficult to obtain
additional financing, and (xv) the risk that the U.S. government's responses
(including inaction) to the national and global economic situation, including
possible courses of action related to the so-called "sequester" may adversely
affect SIGA's business. More detailed information about our company and risk
factors that may affect the realization of forward-looking statements,
including the forward-looking statements set forth here, is set forth in our
filings with the Securities and Exchange Commission (the SEC), including our
Annual Report on Form 10-K for the fiscal year ended December 31, 2011, and in
other documents that we have filed with the SEC. We urge investors and
security holders to read those documents free of charge at the SEC's Web site
at Interested parties may also obtain those documents free
of charge directly from us. Forward-looking statements speak only as of the
date they are made, and except for our ongoing obligations under the federal
securities laws, we undertake no obligation to update publicly any
forward-looking statement whether as a result of new information, future
events or otherwise.

CONTACT: KCSA Strategic Communications
         Todd Fromer / Rob Fink
         212-896-1215 / 1206 /

company logo
Press spacebar to pause and continue. Press esc to stop.